Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking Rivaroxaban

Clinical Cardiology

Volumn 38, Issue 2, 2015, Pages 63-68

  Tamayo, Sally ^a   Peacock, W Frank ^b   Patel, Manesh ^c   Sicignano, Nicholas ^d   Hopf, Kathleen P ^d   Fields, Larry E ^d   Sarich, Troy ^e   Wu, Shujian ^e   Yannicelli, Daniel ^d   Yuan, Zhong ^e  

^a NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^d Health ResearchTx ^*  (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BLOOD CLOTTING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

AGED; ALGORITHM; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DRUG SURVEILLANCE PROGRAM; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; MAJOR BLEEDING; MAJOR CLINICAL STUDY; MALE; NONVALVULAR ATRIAL FIBRILLATION; OBSERVATIONAL STUDY; RECTUM HEMORRHAGE; SUBDURAL HEMATOMA; SYSTEMIC EMBOLISM; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; ELECTRONIC MEDICAL RECORD; EPIDEMIOLOGY; HEMORRHAGE; MILITARY MEDICINE; MORTALITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; ELECTRONIC HEALTH RECORDS; EMBOLISM; FEMALE; HEMORRHAGE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MILITARY MEDICINE; PHARMACOVIGILANCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RIVAROXABAN; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84925650701     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22373     Document Type: Article

References (14)

1. Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114: 1453-1468.
2. Mant J, Edwards D. Stroke prevention in atrial fibrillation: putting the guidelines into practice. Drugs Aging. 2010;27:859-870.
3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104.
4. Granger CB, Alexander JH, McMurray JJ, et al ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;15;365:981-992.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010;363:1877]. N Engl J Med. 2009;361:1139-1151.
6. PatelMR, Mahaffey KW, Garg J, et al ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
7. Turpie AG, Lassen MR, Erikkson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies. Thromb Haemost. 2011;105: 444-453.
8. Goodman SG, Wojdyla DM, Piccini JP, et al ROCKET-AF Investigators. Factors associated with major bleeding events: insights from the Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF). J Am Coll Cardiol. 2014;63:891-900.
9. US Census Bureau. Age and sex composition in the United States: 2011. http://www.census.gov/population/age/data/2011comp.html. Updated November 28, 2012. Accessed May 19, 2014.
10. Cunningham A, SteinCM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20:560-566.
11. Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014; 129:1577-1585.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
13. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263-272.
14. Piccini JP, Garg J, Patel MR, et al ROCKET-AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET-AF trial. Eur Heart J. 2014;35:1873-1880.